Lancet Innovative Drug Trial Kicks Off with Researchers' Meeting at Sirius

In September, at the “Sirius” venue, a meeting of researchers was held, organized by “OCT” for the study initiator – the pharmaceutical company “Lancet.” The event marked the start of a clinical study for an innovative drug in the Russian Federation. Such meetings are a key element in launching clinical studies; their main goal is to unite all participants, from principal investigators to monitors, for a detailed discussion of the protocol, work standards, and ensuring maximum patient safety. 

The event was opened by Irina Petrova, Director of Clinical Operations at “OCT.” In her opening remarks, she emphasized the strategic importance of the project, spoke about the uniqueness of the study design, and expressed confidence in successful collaborative work. 

Senior Project Manager Andrey Stefashin presented the team to the participants who will provide operational support for the project at all stages. He detailed the protocol, inclusion and exclusion criteria, recruitment strategy, as well as all necessary procedures and study endpoints. 

Varvara Ryabova, Product Registration Manager from “Lancet,” noted, “This study is significant for the Russian scientific community and opens new opportunities for the development of innovative therapy in the country. We highly value the professional approach and expertise of the ‘OCT’ team, who act as our partner in realizing this complex project. Together, we are creating a solid foundation for the implementation of modern therapeutic solutions, which aligns with our strategic goals for the development of accessibility to innovative medicine in Russia.” 

As a result of the event, unified approaches to work were formed, participant motivation was strengthened, and an effective communication model was established, necessary for the successful implementation of the project. The OCT team is responsible for the comprehensive “turnkey” management of the project, guaranteeing the achievement of all set goals within the established deadlines. 

OCT CRO possesses proven expertise in the organization and management of clinical research. We offer a full spectrum of services: from the development of clinical study design and medical writing and scientific consulting services to comprehensive project support aimed at drug registration. To calculate costs and discuss your project, please send an inquiry to info@oct-cro.com.